JP2021505553A5 - - Google Patents

Download PDF

Info

Publication number
JP2021505553A5
JP2021505553A5 JP2020529717A JP2020529717A JP2021505553A5 JP 2021505553 A5 JP2021505553 A5 JP 2021505553A5 JP 2020529717 A JP2020529717 A JP 2020529717A JP 2020529717 A JP2020529717 A JP 2020529717A JP 2021505553 A5 JP2021505553 A5 JP 2021505553A5
Authority
JP
Japan
Prior art keywords
independently selected
alkoxy
alkyl
optionally substituted
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020529717A
Other languages
English (en)
Japanese (ja)
Other versions
JP7326276B2 (ja
JP2021505553A (ja
Filing date
Publication date
Priority claimed from GBGB1720101.3A external-priority patent/GB201720101D0/en
Priority claimed from GBGB1817343.5A external-priority patent/GB201817343D0/en
Application filed filed Critical
Priority claimed from PCT/EP2018/082537 external-priority patent/WO2019105886A1/en
Publication of JP2021505553A publication Critical patent/JP2021505553A/ja
Publication of JP2021505553A5 publication Critical patent/JP2021505553A5/ja
Application granted granted Critical
Publication of JP7326276B2 publication Critical patent/JP7326276B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020529717A 2017-12-02 2018-11-26 新規化合物及び疾患の治療のためのその医薬組成物 Active JP7326276B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1720101.3 2017-12-02
GBGB1720101.3A GB201720101D0 (en) 2017-12-02 2017-12-02 Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
GB1817343.5 2018-10-25
GBGB1817343.5A GB201817343D0 (en) 2018-10-25 2018-10-25 Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
PCT/EP2018/082537 WO2019105886A1 (en) 2017-12-02 2018-11-26 Novel compounds and pharmaceutical compositions thereof for the treatment of diseases

Publications (3)

Publication Number Publication Date
JP2021505553A JP2021505553A (ja) 2021-02-18
JP2021505553A5 true JP2021505553A5 (cg-RX-API-DMAC7.html) 2022-01-06
JP7326276B2 JP7326276B2 (ja) 2023-08-15

Family

ID=64564856

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020529717A Active JP7326276B2 (ja) 2017-12-02 2018-11-26 新規化合物及び疾患の治療のためのその医薬組成物

Country Status (24)

Country Link
US (2) US11339166B2 (cg-RX-API-DMAC7.html)
EP (1) EP3717471B1 (cg-RX-API-DMAC7.html)
JP (1) JP7326276B2 (cg-RX-API-DMAC7.html)
KR (1) KR102720958B1 (cg-RX-API-DMAC7.html)
CN (1) CN111433200B (cg-RX-API-DMAC7.html)
AU (1) AU2018374456B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020010364A2 (cg-RX-API-DMAC7.html)
CA (1) CA3084090A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020008066A2 (cg-RX-API-DMAC7.html)
CY (1) CY1125044T1 (cg-RX-API-DMAC7.html)
DK (1) DK3717471T3 (cg-RX-API-DMAC7.html)
ES (1) ES2908283T3 (cg-RX-API-DMAC7.html)
HU (1) HUE057581T2 (cg-RX-API-DMAC7.html)
IL (1) IL274938B2 (cg-RX-API-DMAC7.html)
MA (1) MA51200A (cg-RX-API-DMAC7.html)
MX (1) MX2020005423A (cg-RX-API-DMAC7.html)
MY (1) MY201849A (cg-RX-API-DMAC7.html)
PH (1) PH12020550725B1 (cg-RX-API-DMAC7.html)
PL (1) PL3717471T3 (cg-RX-API-DMAC7.html)
PT (1) PT3717471T (cg-RX-API-DMAC7.html)
SG (1) SG11202004925QA (cg-RX-API-DMAC7.html)
TW (1) TW201930301A (cg-RX-API-DMAC7.html)
WO (1) WO2019105886A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202004025B (cg-RX-API-DMAC7.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2876689C (en) 2012-06-13 2022-04-26 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CA2976790C (en) 2015-02-20 2024-02-27 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2018053373A1 (en) 2016-09-16 2018-03-22 The General Hospital Corporation Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019105886A1 (en) * 2017-12-02 2019-06-06 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
KR102956194B1 (ko) 2018-05-04 2026-04-23 인사이트 코포레이션 Fgfr 억제제의 염
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
GB201907558D0 (en) 2019-05-29 2019-07-10 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
GB201907616D0 (en) * 2019-05-29 2019-07-10 Galapagos Nv Novel compounds and pharmaceutical compositons thereof for the treatment of diseases
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
MX2022006691A (es) 2019-12-04 2022-09-19 Incyte Corp Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
US12012409B2 (en) * 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3174353A1 (en) * 2020-04-08 2021-10-14 Dominic Reynolds Compounds and methods for modulating splicing
AU2021320860A1 (en) * 2020-08-05 2023-02-23 The General Hospital Corporation Salt inducible kinase inhibitors
CN112010860B (zh) * 2020-08-05 2023-03-10 南京纳丁菲医药科技有限公司 苄氧基吡唑并嘧啶化合物和药物组合物及其应用
MX2023003677A (es) * 2020-09-30 2023-06-22 Fl2022 001 Inc Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
JP7805363B2 (ja) 2020-11-02 2026-01-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング EGFR阻害薬としての置換1H-ピラゾロ[4,3-c]及び誘導体
US20240174662A1 (en) * 2021-02-01 2024-05-30 Janssen Biotech, Inc. Small molecule inhibitors of salt inducible kinases
EP4284801A4 (en) * 2021-02-01 2025-04-23 Janssen Biotech, Inc. Small molecule inhibitors of salt inducible kinases
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CN113336751A (zh) * 2021-05-31 2021-09-03 南京谷睿生物科技有限公司 一种高效盐诱导激酶抑制剂及其制备方法
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為fgfr抑制劑之三環雜環
KR20230053049A (ko) * 2021-10-13 2023-04-21 서울대학교산학협력단 류마티스 관절염 예방 또는 치료용 약학적 조성물 및 건강기능식품
CN118119619A (zh) * 2021-10-18 2024-05-31 上海美悦生物科技发展有限公司 Sik抑制剂及其组合物、制备方法和用途
AR128279A1 (es) * 2022-01-19 2024-04-10 Hoffmann La Roche Nuevos derivados de bencimidazol piridina
AR128280A1 (es) * 2022-01-19 2024-04-10 Hoffmann La Roche Derivados de bencimidazol piridina
US20250171438A1 (en) * 2022-02-28 2025-05-29 Agios Pharmaceuticals, Inc. Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations
KR20240154642A (ko) * 2022-02-28 2024-10-25 아지오스 파마슈티컬스 아이엔씨. 페닐알라닌 하이드록실라아제 돌연변이의 안정화에 유용한 화합물 및 방법
CN117843634A (zh) * 2022-05-24 2024-04-09 上海美悦生物科技发展有限公司 Sik抑制剂及其组合物、制备方法和用途
WO2024003208A1 (en) * 2022-07-01 2024-01-04 F. Hoffmann-La Roche Ag Imidazo[4,5-b]pyridine and pyrazolo[1,5-a]pyrimidine derivatives as sik modulators for the treatment of rheumatoid arthritis
US20240124450A1 (en) * 2022-09-21 2024-04-18 Pfizer Inc. Novel SIK Inhibitors
EP4642773A1 (en) * 2022-12-27 2025-11-05 F. Hoffmann-La Roche AG New benzimidazole derivatives
EP4737443A1 (en) 2023-05-24 2026-05-06 Tanabe Pharma Corporation Salt-inducible kinase inhibitory compound and pharmaceutical composition containing same
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用
AR133277A1 (es) 2023-07-19 2025-09-10 Hoffmann La Roche Nuevos derivados de bencimidazol piridina
WO2025017041A1 (en) * 2023-07-19 2025-01-23 F. Hoffmann-La Roche Ag Benzimidazoles as sik-activity modulators
WO2025231112A1 (en) * 2024-05-01 2025-11-06 Nimbus Salacia, Inc. Sik2 modulators and uses thereof
WO2025231117A1 (en) * 2024-05-01 2025-11-06 Nimbus Salacia, Inc. Sik2 modulators and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008279759A1 (en) 2007-07-20 2009-01-29 Merck & Co., Inc. Pyrazolo[1,5-a]pyrimidine derivatives
KR101150581B1 (ko) 2007-07-26 2012-06-11 노파르티스 아게 유기 화합물
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
CA2732520A1 (en) * 2008-08-05 2010-02-11 Merck Sharp & Dohme Corp. Therapeutic compounds
GB201204384D0 (en) * 2012-03-13 2012-04-25 Univ Dundee Anti-flammatory agents
US9260426B2 (en) * 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
AU2016315881B2 (en) * 2015-09-03 2019-09-19 The Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK1A and uses thereof
WO2019105886A1 (en) * 2017-12-02 2019-06-06 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
AU2021320860A1 (en) 2020-08-05 2023-02-23 The General Hospital Corporation Salt inducible kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2020537672A5 (cg-RX-API-DMAC7.html)
JP2018502906A5 (cg-RX-API-DMAC7.html)
RU2017146408A (ru) Тетразамещенные алкеновые соединения и их применение
JP2011529964A5 (cg-RX-API-DMAC7.html)
JP2012518634A5 (cg-RX-API-DMAC7.html)
JP2013513613A5 (cg-RX-API-DMAC7.html)
JP2013531070A5 (cg-RX-API-DMAC7.html)
JP2011502956A5 (cg-RX-API-DMAC7.html)
JP2013509431A5 (cg-RX-API-DMAC7.html)
JP2009515949A5 (cg-RX-API-DMAC7.html)
JP2024519487A5 (cg-RX-API-DMAC7.html)
JP2004536066A5 (cg-RX-API-DMAC7.html)
JP2007538024A5 (cg-RX-API-DMAC7.html)
JP2017504576A5 (cg-RX-API-DMAC7.html)
JP2016535772A5 (cg-RX-API-DMAC7.html)
JP2010532386A5 (cg-RX-API-DMAC7.html)
JP2013502431A5 (cg-RX-API-DMAC7.html)
JP2019537603A5 (cg-RX-API-DMAC7.html)
JP2020534264A5 (cg-RX-API-DMAC7.html)
JP2019531279A5 (cg-RX-API-DMAC7.html)
JP2020521766A5 (cg-RX-API-DMAC7.html)
CA2524054A1 (en) Immunosuppressant compounds and compositions
JP2022526553A5 (cg-RX-API-DMAC7.html)
JP2016503785A5 (cg-RX-API-DMAC7.html)
JP2008516968A5 (cg-RX-API-DMAC7.html)